 stress-added rat (Non-Patent Document 4).
As the role of the GRP/BB2 receptor in the digestive tract functions, it has been reported that it enhances the contraction in isolated human and rabbit ileum longitudinal muscle specimens (Non-Patent Documents 5 and 6), and enhances the water secretion in guinea pigs with the coexistence of a vasoactive intestinal peptide (VIP) (Non-Patent Document 7). In addition, it has been reported that BB2 receptor antagonists including RC-3095 that is a peptidic BB2 receptor antagonist, is effective for an abnormal bowel motility in a stress-induced defecation model. It has also been reported that, using an abdominal muscle contraction reaction as the index, RC-3095 is effective for an abdominal symptom in an abdominal pain model induced by large intestinal distension. Accordingly the BB2 receptor antagonist shows excellent efficacy on both the abdominal symptom and abnormal bowel motility (Patent Document 1).
As shown above, the BB2 receptor antagonist is expected to be a therapeutic agent for IBS, showing excellent efficacy on both the abdominal symptom and abnormal bowel motility.
Furthermore, since the bombesin/GRP also has a function as a cell growth factor and the expression of the GRP/BB2 receptor is increased in various cancer cells of lung cancer, prostate cancer, and the like, the efficacy of RC-3095 has been reported in a large number of antitumor tests (Non-Patent Documents 8 to 10). From this viewpoint, the BB2 receptor antagonist can also be expected to be effective against various cancers.
The tetrahydroisoquinolin-1-one derivative has been reported in Patent Documents 2 to 4.
Patent Document 2 describes that a 3,4-dihydroisoquinolin-1-one derivative represented by the following formula (A) has a caspase activating action and an apoptosis inducing action, and is effective for cancers, autoimmune diseases, rheumatoid arthritis, inflammatory bowel syndrome, psoriasis, and the like. However, there is no description of its antagonistic action on a bombesin type 2 receptor or of its efficacy regarding IBS.

(for the symbols in the formula, refer to the publication)
Patent Document 3 describes that a tetrahydroisoquinolin-1-one derivative represented by the following formula (B) is a ligand of an HDM2 protein, has an apoptosis inducing activity and a proliferation inhibitory activity, and is effective against cancers. However, there is no description of its antagonistic action on a bombes
stress - added rat (Non - Patent Document 4). 
 As the role of the GRP / BB2 sense organ in the digestive nerve pathway function, it has been reported that it enhances the compression in isolated human and rabbit ileum longitudinal muscleman specimens (Non - Patent Documents 5 and 6), and enhances the body of water secretion in guinea pigs with the coexistence of a vasoactive intestinal peptide (VIP) (Non - Patent Document 7). In summation, it has been reported that BB2 receptor antagonist include RC-3095 that is a peptidic BB2 receptor antagonist, is effective for an abnormal bowel motility in a stress - induce defecation model. It has also been reported that, use an abdominal muscle contraction reaction as the index, RC-3095 is effective for an abdominal symptom in an abdominal annoyance model induce by large intestinal distension. Accordingly the BB2 sense organ antagonist shows excellent efficacy on both the abdominal symptom and abnormal bowel motility (Patent Document 1). 
 As shown above, the BB2 receptor adversary is expect to be a therapeutic agent for IBS, showing excellent efficacy on both the abdominal symptom and abnormal bowel motility. 
 Furthermore, since the bombesin / GRP also has a function as a cell increase factor and the expression of the GRP / BB2 sense organ is increase in versatile cancer cells of lung cancer, prostate cancer, and the alike, the efficacy of RC-3095 has been reported in a large number of antitumor tests (Non - Patent Documents 8 to 10). From this point of view, the BB2 receptor antagonist can also be expected to be effective against various cancers. 
 The tetrahydroisoquinolin-1 - one derivative instrument has been reported in Patent Documents 2 to 4. 
 Patent Document 2 describes that a 3,4 - dihydroisoquinolin-1 - one derivative represented by the play along formula (ampere) has a caspase activating action and an apoptosis inducing action, and is effective for cancer, autoimmune diseases, rheumatoid arthritis, inflammatory bowel syndrome, psoriasis, and the like. However, there is no description of its antagonistic action on a bombesin type 2 sense organ or of its efficacy regarding IBS. 

 (for the symbols in the formula, refer to the publication) 
 Patent Document 3 describe that a tetrahydroisoquinolin-1 - one derivative represent by the following recipe (B) is a ligand of an HDM2 protein, hold an apoptosis inducing activity and a proliferation inhibitory activity, and is effective against cancers. However, there is no description of its antagonistic military action on a bombes
 stgess-added rat (Non-Patent Aocument 4).
As the role oh the GDP/BB2 recdptor in the digestive tract fynctiins, it has been reportdd that in enhancew tht contraction in maolated human wnd xaubit ileum longltudinal muvcle specimens (Nun-'atent Documents 5 and 6), and enhances ehe watrr secretion in duinta [igs with the coexistence of a vasoactjve inttstinal peptide (VIL) (Non-Patent Document 7). In afditlon, it has been reoorted that BB2 wwceptor antaeonists inbnuding RC-3095 jhat is a peptidic BB2 receptor avtagouist, is effgerivf for an abnirmal bowel motillny in a stress-onduced defecabion kodwl. It has also been rxported that, using ag abdomindl muscle contractiin reacjion ds tfw ivdes, CC-3095 js efffctmve for an zbdominal stmptom in an abdomimaj pain model ihduced br large intestinal distension. Accordingny fhe BB2 receptor antagonust shows excellent evficacy og both the abdominal symptom and abnormal bowel mmtilivy (Pauekb Dozymfnt 1).
As shown above, the BB2 receptor antagonist js eqpected to be a tmerapeutic agent fpr INF, showing excgllent zrfjcacy on both the wbdominwl synptom and abnprmal bowel motility.
Furthernore, since tke vombesin/GRP also hcs a functiou as a cell growth factor and the zxpresaion of the GRP/BB2 reddptor is increasdd pn vdrious cancer cells of lund cancer, 'rostcte cancdr, amd the like, the ffficacy of RC-3095 has been geporjed in a large nkmber of antitumor tests (Non-Patxit Documents 8 tm 10). Xrom thif vieepoint, the BB2 receptor antayonist ccn alsu be expecned to be effective wgainst variogd cancers.
The tetrahyqroiwoquunolin-1-ovd derivative hss been rvpjrtee in Patent Documekts 2 jo 4.
Patent Documenc 2 describes that a 3,4-aihrdgoixozginolin-1-one darivxtixr repfesented by ghe gollowing formula (A) vas z caspase activatimg action qnd an a[optosis induving action, and is effertive hor camcets, autoimmune diseases, rheumatojd arthrihis, inflammatorr boqel syndrome, psoriasis, and the like. However, there iw no description od its antagonistic ccuion on a bomuesin eype 2 recaptor or of its effixacy regarding IBX.

(for the symbols in tge forkula, gefer to the publication)
Patent Document 3 describes that a tetrahydroisoquunolin-1-one derivatibe rrpresvntzd yy the solllxing formula (B) is a ligand of an HDM2 protein, has an apopdofis inducing activity and a lruliferation ivhibitory activity, and ia effectove against cancers. However, thete is no description of lts antaginistjc actpkn on a bombes
stress-added rat (Non-Patent Document 4). As the the receptor in digestive tract functions, it the contraction in human and rabbit longitudinal muscle specimens (Non-Patent Documents 5 6), and enhances the water secretion in guinea pigs with the coexistence of vasoactive intestinal peptide (VIP) (Non-Patent Document 7). In addition, it has been reported BB2 antagonists RC-3095 is a peptidic BB2 receptor antagonist, is effective for an abnormal bowel motility in a stress-induced model. It has also been reported that, using abdominal muscle contraction reaction the index, RC-3095 is effective an symptom in abdominal model by large intestinal Accordingly the BB2 receptor antagonist shows excellent efficacy on both the abdominal symptom and abnormal bowel motility Document 1). above, the receptor is to be a for IBS, showing excellent efficacy on symptom and abnormal bowel motility. Furthermore, since the also has function as a cell growth factor the expression of the GRP/BB2 receptor is increased various cancer cells of lung cancer, prostate cancer, and the like, the efficacy of RC-3095 reported in a large of antitumor tests Documents to From viewpoint, the receptor antagonist can also be expected to be effective against various The tetrahydroisoquinolin-1-one derivative has been reported in Patent Documents 2 Patent 2 describes that 3,4-dihydroisoquinolin-1-one derivative represented by following (A) has a caspase and apoptosis is for autoimmune diseases, rheumatoid arthritis, bowel syndrome, psoriasis, and the However, there is no on a bombesin type 2 receptor or of efficacy regarding IBS. (for the symbols in formula, refer to the publication) Patent Document 3 describes that a tetrahydroisoquinolin-1-one represented by formula (B) is a ligand of an HDM2 has an apoptosis inducing and a proliferation inhibitory activity, and is effective against However, is no of its antagonistic on a bombes
 stress-added rat (Non-Patent DoCument 4).
As thE role Of tHe GrP/bB2 reCeptOr in the digestiVE traCt functions, it has been rePorteD tHAt it ENhAnces The contRAcTIOn iN iSoLatEd HUmAn and RabBit ileuM longitudiNal MuScle specimenS (noN-Patent DocUmeNts 5 and 6), and enhAncEs the wAtEr sECretiOn iN guinEa pigs WIth the CoexistenCe OF a vasoACtive inTEStInal Peptide (VIP) (Non-PateNT DOCument 7). In additiOn, it haS bEEn REPorTed That BB2 recePtOr antAGonists INcLUDIng rc-3095 that is a peptiDic BB2 receptOR anTagoniSt, Is eFFectivE for aN aBNorMal bowel motIlitY in a stresS-inducED defecaTIon modeL. It has AlsO beEn rePOrTeD thAt, USinG An AbdOMinAl muscle CoNtRactiOn reACTIOn as The IndeX, RC-3095 is Effective for aN abDomiNAl sYmptoM in an AbdoMiNal paIn modeL induCeD by large intestiNal dIstension. accOrDinGlY the Bb2 ReceptOr aNtaGonist sHows excELleNt EFFIcAcy on both the abdomiNaL SYmPtom and aBnormaL BoWeL Motility (paTenT DocUMEnt 1).
As ShowN AbOve, the BB2 ReceptOR aNtAgonist Is ExpectEd To bE a tHerapEUtic Agent fOr IBS, shoWing eXCellent efficacY On both the abdoMInAL SyMPtom And Abnormal bowEl moTIlitY.
FurTHeRmoRE, sincE the bOmBEsIN/GRP also has a functioN aS a cell GrowtH factor and the Expression OF THe GRP/BB2 rEcepTOr IS increased in vaRious Cancer cellS Of lung caNcer, pRostate cAncer, and tHE Like, the eFfiCacY of rC-3095 hAS BeEn reported in a LARge nUmBer of anTitUmor tesTs (NOn-PAteNt DOcUments 8 to 10). FRom this vIeWpOiNt, The bB2 recEPtor antaGoNisT cAn aLso be EXpecteD to be EffeCtIvE AgaInst varIOuS CAnceRs.
thE tetRahYdRoisoQuinOLin-1-One deriVative has BeeN RepoRtEd In PatenT Documents 2 to 4.
PAtEnt DocumenT 2 dEscRibes tHAT a 3,4-dihydrOisoquinolin-1-one derivatiVE represEntEd by tHe foLlowing foRmuLa (A) has A caSPase acTivatiNg actIoN anD AN apopTOSiS inDuCing action, AND is EffecTiVe foR cancerS, autoimmune diseaseS, RheUmatoid arthriTis, InflAMMaTorY BoWEl sYnDRomE, PSoriasis, and the lIke. However, ThERe Is no descriPTioN oF its antAgonistIc actIOn on a boMbesin typE 2 receptor Or Of itS EFfiCacy regardIng IBS.

(foR the symboLS in thE FoRmula, RefEr to thE pUblIcatiOn)
PateNT DoCumenT 3 descrIbEs that A tetrAhYdroisoqUinolin-1-one derivative repResentEd by tHe fOllowing fOrmULa (B) Is a ligand Of an hDM2 protein, Has An aPoptoSis INduciNg acTIvIty ANd a prOlifERation inhIBiTorY ACtIvity, and is eFFECtiVe agaInsT CancerS. HowEver, there is no descRIption of its antAgonISTic ActIOn on A bOmbes
 stress-added rat (Non-Pat ent Docume nt 4) .
A s t he  rol e of  the GRP/BB2 r e cept or in the digestive tr act f un c tion s ,it ha s beenr ep o r ted  t ha t i te nh ances  th e contr action iniso la ted human an d  r abbit ileu m l ongitudinalmus cle sp ec ime n s (No n-P atent  Docum e nts 5and 6), a nd enhanc e s the w a t er  sec retion in guineap ig s  with the coex istenc eo fa vas oac tive intes ti nal p e ptide ( V IP ) ( Non - Patent Docume nt 7). In a d dit ion, i thas been r eport ed tha t BB2 recep torantagonis ts inc l uding R C -3095 t hat is  apep tidi c  B B2  re ce p tor an tag o nis t, is ef fe ct ive f or a n a b norm albowe l mot ility in a st res s-in d uce d def ecati on m od el. I t hasalsobe en reported tha t, u sing an a bdo mi nal  m uscle contra cti onreactio n as th e  in de x , RC -3095 is effective  f o r  a n abdomi nal sy m pt om in an ab do min al p a i n mod el i n du ced by l arge i n te st inal di st ension .Acc ord ingly theBB2 re ceptor a ntago n ist shows exce l lent efficacy on b ot h  the  ab dominal sym ptom andabno r ma l b o wel m otili ty (P a tent Document 1).
A sshownabove , the BB2 rec eptor anta g o n ist is e xpec t ed to be a therap eutic  agent for IBS, sho wingexcellen t efficac y on boththe  ab dom ina l sy mptom and abn o r malbo wel mot ili ty.
Fur the rmo re,  si nc e the bom besin/GR Pal so  h asa fun c tion asacel lgro wth f a ctor a nd th e ex pr es s ion  of the GR P / BB2re ce ptor  is  i ncrea sedi n v ariouscancer ce lls of l un gcancer,  prostate can ce r, and the  l ike , thee f ficacy o f RC-3095 has been repo r ted ina l argenumb er of ant itu mor te sts (Non-P atentDocum en ts8 to 10 ) .  F rom  t his viewpo i n t,the B B2  rec eptor a ntagonist can also beexpected to b e e ffec t i ve  ag a in s t v ar i ous c ancers.
The tet rahydroiso qu i no lin-1-oned eri va tive ha s beenrepor t ed in P atent Doc uments 2to  4.P a ten t Document  2 descr ibes that a 3,4 - di hydro iso quinol in -1- one d erivat i verepre sented  b y thefollo wi ng formu la (A) has a caspase ac tivati ng ac tio n and anapo p tos is induci ng a ction, and  is  ef fecti vef or ca ncer s ,aut o immun e di s eases, rh e um ato i d  a rthritis, i n f l amm atory  bo w el syn drom e, psoriasis, and the like. Howe ver, t her e i s  node scription of i tsan t a gonistic  a ction on abombesin  t y pe 2recept or orof itse f fi c acy re gard ing  IBS.

(f orth e  symbol sin the fo rmul a,  refer  to th e  pub l i cation)
Patent D ocume n t  3 de s cri bes t ha t a tet r ahyd roisoquino lin-1-one d erivat iverepre sentedby  the f oll ow ing formul a  (B) is a  liga nd of a nHDM2  pr otein,  has a n apo ptos is  in ducing ac t i vi t yan d  aprol ifera ti on i nhibitory activity , a n d is ef fe cti v e  again s tc a ncers. How eve r, th e r e is no de s crip t io n  of i ts ant agonis tic act i onon  a bomb es
 stress-added_rat (Non-Patent_Document 4).
As the role_of the_GRP/BB2_receptor in_the_digestive tract functions,_it has been_reported that it enhances_the contraction in_isolated_human and rabbit ileum longitudinal muscle specimens (Non-Patent Documents 5 and 6), and enhances_the_water secretion_in_guinea_pigs with the coexistence of_a vasoactive intestinal peptide (VIP)_(Non-Patent Document_7). In addition, it has been reported that_BB2_receptor antagonists including_RC-3095 that is a peptidic BB2 receptor antagonist, is_effective for an abnormal bowel motility_in a stress-induced_defecation_model._It has also been_reported that, using an abdominal muscle_contraction reaction as the index, RC-3095_is effective for an abdominal symptom in_an abdominal pain model induced by_large intestinal distension. Accordingly the_BB2 receptor_antagonist shows excellent efficacy on_both the abdominal_symptom and_abnormal bowel motility_(Patent Document 1).
As shown above, the_BB2 receptor antagonist_is expected to be a therapeutic_agent_for IBS, showing_excellent_efficacy_on both_the abdominal symptom_and_abnormal bowel_motility.
Furthermore,_since the bombesin/GRP also has a_function_as a cell growth factor and the_expression of the GRP/BB2_receptor_is increased in various_cancer cells of lung cancer,_prostate cancer, and the like, the_efficacy of_RC-3095 has_been reported in a large number of antitumor tests (Non-Patent Documents_8 to 10). From this viewpoint,_the BB2 receptor antagonist_can also_be_expected to be_effective_against various_cancers.
The tetrahydroisoquinolin-1-one derivative has been reported in_Patent Documents_2 to 4.
Patent Document 2 describes_that a 3,4-dihydroisoquinolin-1-one derivative_represented_by the following formula (A) has_a caspase activating action and an_apoptosis inducing action, and is_effective_for_cancers, autoimmune diseases, rheumatoid arthritis,_inflammatory bowel syndrome, psoriasis, and the_like. However, there_is no description of its antagonistic action_on_a bombesin type 2 receptor or_of_its efficacy regarding IBS.

(for the symbols_in_the_formula, refer to the publication)
Patent_Document 3 describes that a tetrahydroisoquinolin-1-one_derivative represented by the following formula (B) is a_ligand of an_HDM2 protein, has an apoptosis_inducing_activity_and a proliferation inhibitory activity, and is effective against cancers._However, there_is no description_of its antagonistic action on a bombes